Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2–p53 interaction, in rats, dogs and monkeys: in vitro–in vivo correlation

Qiuping YeDepartment of Pharmacokinetics and Drug Metabolism and Correspondence[email protected]

Min JiangDepartment of Pharmacokinetics and Drug Metabolism and

Wotang T. HuangDepartment of Pharmacokinetics and Drug Metabolism and

Yun LingDepartment of Pharmacokinetics and Drug Metabolism and

Steven H. OlsonDepartment of Therapeutic Discovery, Amgen Inc., South San Francisco, CA, USA

Daqing SunDepartment of Therapeutic Discovery, Amgen Inc., South San Francisco, CA, USA

Guifen XuDepartment of Pharmacokinetics and Drug Metabolism and

Xuelei YanDepartment of Therapeutic Discovery, Amgen Inc., South San Francisco, CA, USA

Bradley K. WongDepartment of Pharmacokinetics and Drug Metabolism and

Lixia JinDepartment of Pharmacokinetics and Drug Metabolism and

Your download is now in progress and you may close this window